Similar companies
Income Statement (USD)
Q2 '24 | QoQ | |
---|---|---|
Revenue | 660M | 43.7% |
Gross Profit | 344M | 77.7% |
Cost of Revenue | 316M | 18.9% |
Operating expense | 543M | 15% |
Net Income | -17M | 74.4% |
EBITDA | 64M | 312.6% |
Balance Sheet (USD)
Q2 '24 | QoQ | |
---|---|---|
Total Assets | 4.01B | 4.8% |
Total Liabilities | 4.01B | 0.8% |
Shares Outstanding | 128M | 1.2% |
Cash Flow (USD)
Q2 '24 | QoQ | |
---|---|---|
Cash from operations | 124M | 252.3% |
Cash from investing | 34M | 150.2% |
Cash from financing | 131M | 354.8% |
EPS
Financial Highlights for Alnylam Pharmaceuticals in Q2 '24
Alnylam Pharmaceuticals reported a revenue of 660M, which is a 43.7% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 344M, marking a 77.7% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 316M, a 18.9% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 543M, showing a 15% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -17M, showing a 74.4% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 64M, showing a 312.6% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Alnylam Pharmaceuticals with growth in revenue, gross profit, and net income. Higher operating expenses might indicate increased investments or potential inefficiencies.